CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells

• Published in: BMB reports Vol. 53; no. 12; pp. 622 - 627
• Main Authors: Kim, Dae Kyoung, Ham, Min Hee, Lee, Seo Yul, Shin, Min Joo, Kim, Ye Eun, Song, Parkyong, Suh, Dong-Soo, Kim, Jae Ho
• Format: Journal Article
• Language: Korean
• Published: 생화학분자생물학회 31.12.2020
• Subjects: ALCAM; Cancer stem cells; CD166; Chemoresistance; Ovarian cancer; ALCAM; Cancer stem cells; Chemoresistance; CD166; Ovarian cancer
• ISSN: 1976-6696; 1976-670X

Cancer stem cells (CSCs) or tumor-initiating cells are thought to play critical roles in tumorigenesis, metastasis, drug resistance, and tumor recurrence. For the diagnosis and targeted therapy of CSCs, the molecular identity of biomarkers or therapeutic targets for CSCs needs to be clarified. In this study, we identified CD166 as a novel marker expressed in the sphereforming CSC population of A2780 epithelial ovarian cancer cells and primary ovarian cancer cells. The CD166+ cells isolated from A2780 cells and primary ovarian cancer cells highly expressed CSC markers, including ALDH1a1, OCT4, and SOX2, and ABC transporters, which are implicated in the drug resistance of CSCs. The CD166+ cells exhibited enhanced CSC-like properties, such as increased sphere-forming ability, cell migration and adhesion abilities, resistance to conventional anticancer drugs, and high tumorigenic potential in a xenograft mouse model. Knockdown of CD166 expression in the sphereforming ovarian CSCs abrogated their CSC-like properties. Moreover, silencing of CD166 expression in the sphere-forming CSCs suppressed the phosphorylation of focal adhesion kinase, paxillin, and SRC. These results suggest that CD166 plays a key role in the regulation of CSC-like properties and focal adhesion kinase signaling in ovarian cancer. [BMB Reports 2020; 53(12): 622-627]